PDE7 inhibitor TC3.6 ameliorates symptomatology in a model of primary progressive multiple sclerosis

British Journal of Pharmacology

Volumn 172, Issue 17, 2015, Pages 4277-4290

  Mestre, L ^a   Redondo, M ^b   Carrillo Salinas, F J ^a   Morales Garcia J A ^c,d   Alonso Gil, S ^c,d   Pérez Castillo, A ^c,d   Gil, C ^e   Martínez, A ^e   Guaza, C ^a  

^a INSTITUTO CAJAL   (Spain)

^b INSTITUTO DE QUÍMICA MÉDICA   (Spain)

^c CSIC   (Spain)

^d CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^e CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; PHOSPHODIESTERASE VII INHIBITOR; RL 50481; TC 3.6; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE VII;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY TEST; DISEASE SEVERITY; DRUG EFFICACY; DRUG STRUCTURE; GENE EXPRESSION REGULATION; IFN GAMMA GENE; IL 1BETA GENE; IL 6 GENE; IN VIVO STUDY; MOTOR DYSFUNCTION; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THEILER'S MURINE ENCEPHALOMYELITIS VIRUS; THEILERIOSIS; TNF ALPHA GENE; TREATMENT OUTCOME; VIRUS ENCEPHALITIS; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; DISEASE MODEL; ENZYMOLOGY; FEMALE; METABOLISM; MOUSE; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; NEWBORN; PATHOLOGY; PC12 CELL LINE; RAT;

ANIMALS; ANIMALS, NEWBORN; CELLS, CULTURED; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 7; DISEASE MODELS, ANIMAL; FEMALE; MICE; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; PC12 CELLS; PHOSPHODIESTERASE INHIBITORS; RATS;

EID: 84938704564     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13192     Document Type: Article

References (56)

1. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, etal. (2013). The Concise Guide to PHARMACOLOGY 2013/14: enzymes. Br J Pharmacol 170: 1797-1867.
2. Arevalo-Martin A, Vela JM, Molina-Holgado E, Borrell J, Guaza C, (2003). Therapeutic action of cannabinoids in a murine model of multiple sclerosis. J Neurosci 23: 2511-2516.
3. Arevalo-Martin A, Garcia-Ovejero D, Molina-Holgado E, (2010). The endocannabinoid 2-arachidonoylglycerol reduces lesion expansion and white matter damage after spinal cord injury. Neurobiol Dis 38: 304-312.
4. Bender AT, Beavo JA, (2006). Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 58: 488-520.
5. Brudvik KW, Tasken K, (2012). Modulation of T cell immune functions by the prostaglandin E(2)-cAMP pathway in chronic inflammatory states. Br J Pharmacol 166: 411-419.
6. Carlson NG, Hill KE, Tsunoda I, Fujinami RS, Rose JW, (2006). The pathologic role for COX-2 in apoptotic oligodendrocytes in virus induced demyelinating disease: implications for multiple sclerosis. J Neuroimmunol 174: 21-31.
7. Claveau D, Chen SL, O'Keefe S, Zaller DM, Styhler A, Liu S, etal. (2004). Preferential inhibition of T helper 1, but not T helper 2, cytokines in vitro by L-826,141 [4-[2-(3,4-Bisdifluromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan- 2-yl)-phenyl]-ethyl]3-methylpyridine-1-oxide], a potent and selective phosphodiesterase 4 inhibitor. J Pharmacol Exp Ther 310: 752-760.
8. Comi G, (2013). Disease-modifying treatments for progressive multiple sclerosis. Mult Scler 19: 1428-1436.
9. Curtin F, Hartung HP, (2014). Novel therapeutic options for multiple sclerosis. Expert Rev Clin Pharmacol 7: 91-104.
10. Garcia AM, Brea J, Morales-Garcia JA, Perez DI, Gonzalez A, Alonso-Gil S, etal. (2014). Modulation of cAMP-specific PDE without emetogenic activity: new sulfide-like PDE7 inhibitors. J Med Chem 57: 8590-8607.
11. Giembycz MA, (2005). Life after PDE4: overcoming adverse events with dual-specificity phosphodiesterase inhibitors. Curr Opin Pharmacol 5: 238-244.
12. Giembycz MA, Dent G, (1992). Prospects for selective cyclic nucleotide phosphodiesterase inhibitors in the treatment of bronchial asthma. Clin Exp Allergy 22: 337-344.
13. Giembycz MA, Smith SJ, (2006). Phosphodiesterase 7A: a new therapeutic target for alleviating chronic inflammation? Curr Pharm Des 12: 3207-3220.
14. Gonzalez-Garcia C, Bravo B, Ballester A, Gomez-Perez R, Eguiluz C, Redondo M, etal. (2013). Comparative assessment of PDE 4 and 7 inhibitors as therapeutic agents in experimental autoimmune encephalomyelitis. Br J Pharmacol 170: 602-613.
15. Goto M, Murakawa M, Kadoshima-Yamaoka K, Tanaka Y, Inoue H, Murafuji H, etal. (2009). Phosphodiesterase 7A inhibitor ASB16165 suppresses proliferation and cytokine production of NKT cells. Cell Immunol 258: 147-151.
16. Johansson EM, Reyes-Irisarri E, Mengod G, (2012). Comparison of cAMP-specific phosphodiesterase mRNAs distribution in mouse and rat brain. Neurosci Lett 525: 1-6.
17. Kaminuma O, Mori A, Wada K, Kikkawa H, Ikezawa K, Suko M, etal. (1998). A selective type 4 phosphodiesterase inhibitor, T-440, modulates intracellular cyclic AMP level and interleukin-2 production of Jurkat cells. Immunopharmacology 38: 247-252.
18. Karussis D, (2014). The diagnosis of multiple sclerosis and the various related demyelinating syndromes: a critical review. J Autoimmun 48-49: 134-142.
19. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: Reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
20. Kipp M, van der Valk P, Amor S, (2012). Pathology of multiple sclerosis. CNS Neurol Disord Drug Targets 11: 506-517.
21. Lee R, Wolda S, Moon E, Esselstyn J, Hertel C, Lerner A, (2002). PDE7A is expressed in human B-lymphocytes and is up-regulated by elevation of intracellular cAMP. Cell Signal 14: 277-284.
22. Loria F, Petrosino S, Hernangomez M, Mestre L, Spagnolo A, Correa F, etal. (2010). An endocannabinoid tone limits excitotoxicity in vitro and in a model of multiple sclerosis. Neurobiol Dis 37: 166-176.
23. Ludwin SK, (2006). The pathogenesis of multiple sclerosis: relating human pathology to experimental studies. J Neuropathol Exp Neurol 65: 305-318.
24. Makranz C, Cohen G, Reichert F, Kodama T, Rotshenker S, (2006). cAMP cascade (PKA, Epac, adenylyl cyclase, Gi, and phosphodiesterases) regulates myelin phagocytosis mediated by complement receptor-3 and scavenger receptor-AI/II in microglia and macrophages. Glia 53: 441-448.
25. Malone M, Gary D, Yang IH, Miglioretti A, Houdayer T, Thakor N, etal. (2013). Neuronal activity promotes myelination via a cAMP pathway. Glia 61: 843-854.
26. Martinez A, Gil C, (2014). cAMP-specific phosphodiesterase inhibitors: promising drugs for inflammatory and neurological diseases. Expert Opin Ther Pat 24: 1311-1321.
27. Maurice DH, Ke H, Ahmad F, Wang Y, Chung J, Manganiello VC, (2014). Advances in targeting cyclic nucleotide phosphodiesterases. Nat Rev Drug Discov 13: 290-314.
28. McCarthy DP, Richards MH, Miller SD, (2012). Mouse models of multiple sclerosis: experimental autoimmune encephalomyelitis and Theiler's virus-induced demyelinating disease. Methods Mol Biol 900: 381-401.
29. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
30. Mecha M, Iñigo PM, Mestre L, Hernangõmez M, Borrell J, Guaza C, (2011). An easy and fast way to obtain a high number of glial cells from rat cerebral tissue: a beginners approach. Protocol Exchange. doi: 10.1038/protex.2011.1218
31. Mecha M, Carrillo-Salinas FJ, Mestre L, Feliu A, Guaza C, (2013). Viral models of multiple sclerosis: neurodegeneration and demyelination in mice infected with Theiler's virus. Prog Neurobiol 101-102: 46-64.
32. Medina-Rodriguez EM, Arenzana FJ, Pastor J, Redondo M, Palomo V, Garcia de Sola R, etal. (2013). Inhibition of endogenous phosphodiesterase 7 promotes oligodendrocyte precursor differentiation and survival. Cell Mol Life Sci 70: 3449-3462.
33. Mestre L, Correa F, Docagne F, Clemente D, Guaza C, (2006). The synthetic cannabinoid WIN 55,212-2 increases COX-2 expression and PGE2 release in murine brain-derived endothelial cells following Theiler's virus infection. Biochem Pharmacol 72: 869-880.
34. Mestre L, Docagne F, Correa F, Loria F, Hernangomez M, Borrell J, etal. (2009). A cannabinoid agonist interferes with the progression of a chronic model of multiple sclerosis by downregulating adhesion molecules. Mol Cell Neurosci 40: 258-266.
35. Miro X, Perez-Torres S, Palacios JM, Puigdomenech P, Mengod G, (2001). Differential distribution of cAMP-specific phosphodiesterase 7A mRNA in rat brain and peripheral organs. Synapse 40: 201-214.
36. Morales-Garcia JA, Redondo M, Alonso-Gil S, Gil C, Perez C, Martinez A, etal. (2011). Phosphodiesterase 7 inhibition preserves dopaminergic neurons in cellular and rodent models of Parkinson disease. PLoS ONE 6: e17240.
37. Muise ES, Chute IC, Claveau D, Masson P, Boulet L, Tkalec L, etal. (2002). Comparison of inhibition of ovalbumin-induced bronchoconstriction in guinea pigs and in vitro inhibition of tumor necrosis factor-alpha formation with phosphodiesterase 4 (PDE4) selective inhibitors. Biochem Pharmacol 63: 1527-1535.
38. Njenga MK, Coenen MJ, DeCuir N, Yeh HY, Rodriguez M, (2000). Short-term treatment with interferon-alpha/beta promotes remyelination, whereas long-term treatment aggravates demyelination in a murine model of multiple sclerosis. J Neurosci Res 59: 661-670.
39. Paintlia AS, Paintlia MK, Singh I, Skoff RB, Singh AK, (2009). Combination therapy of lovastatin and rolipram provides neuroprotection and promotes neurorepair in inflammatory demyelination model of multiple sclerosis. Glia 57: 182-193.
40. Paterniti I, Mazzon E, Gil C, Impellizzeri D, Palomo V, Redondo M, etal. (2011). PDE 7 inhibitors: new potential drugs for the therapy of spinal cord injury. PLoS ONE 6: e15937.
41. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, etal.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucl Acids Res 42 (Database Issue): D1098-D1106.
42. Perez-Gonzalez R, Pascual C, Antequera D, Bolos M, Redondo M, Perez DI, etal. (2013). Phosphodiesterase 7 inhibitor reduced cognitive impairment and pathological hallmarks in a mouse model of Alzheimer's disease. Neurobiol Aging 34: 2133-2145.
43. Perez-Torres S, Cortes R, Tolnay M, Probst A, Palacios JM, Mengod G, (2003). Alterations on phosphodiesterase type 7 and 8 isozyme mRNA expression in Alzheimer's disease brains examined by in situ hybridization. Exp Neurol 182: 322-334.
44. Petzold A, Baker D, Pryce G, Keir G, Thompson EJ, Giovannoni G, (2003). Quantification of neurodegeneration by measurement of brain-specific proteins. J Neuroimmunol 138: 45-48.
45. Redondo M, Brea J, Perez DI, Soteras I, Val C, Perez C, etal. (2012a). Effect of phosphodiesterase 7 (PDE7) inhibitors in experimental autoimmune encephalomyelitis mice. Discovery of a new chemically diverse family of compounds. J Med Chem 55: 3274-3284.
46. Redondo M, Palomo V, Brea J, Perez DI, Martin-Alvarez R, Perez C, etal. (2012b). Identification in silico and experimental validation of novel phosphodiesterase 7 inhibitors with efficacy in experimental autoimmune encephalomyelitis mice. ACS Chem Neurosci 3: 793-803.
47. Redondo M, Zarruk JG, Ceballos P, Perez DI, Perez C, Perez-Castillo A, etal. (2012c). Neuroprotective efficacy of quinazoline type phosphodiesterase 7 inhibitors in cellular cultures and experimental stroke model. Eur J Med Chem 47: 175-185.
48. Reyes-Irisarri E, Perez-Torres S, Mengod G, (2005). Neuronal expression of cAMP-specific phosphodiesterase 7B mRNA in the rat brain. Neuroscience 132: 1173-1185.
49. Robichaud A, Savoie C, Stamatiou PB, Tattersall FD, Chan CC, (2001). PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway. Neuropharmacology 40: 262-269.
50. Sanchez AJ, Puerta C, Ballester S, Gonzalez P, Arriaga A, Garcia-Merino A, (2005). Rolipram impairs NF-kappaB activity and MMP-9 expression in experimental autoimmune encephalomyelitis. J Neuroimmunol 168: 13-20.
51. Sato F, Tanaka H, Hasanovic F, Tsunoda I, (2011). Theiler's virus infection: pathophysiology of demyelination and neurodegeneration. Pathophysiology 18: 31-41.
52. Sommer N, Loschmann PA, Northoff GH, Weller M, Steinbrecher A, Steinbach JP, etal. (1995). The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nat Med 1: 244-248.
53. Tasken K, Stokka AJ, (2006). The molecular machinery for cAMP-dependent immunomodulation in T-cells. Biochem Soc Trans 34: 476-479.
54. Tsunoda I, Fujinami RS, (2010). Neuropathogenesis of Theiler's murine encephalomyelitis virus infection, an animal model for multiple sclerosis. J Neuroimmune Pharmacol 5: 355-369.
55. Van Wauwe J, Aerts F, Walter H, de Boer M, (1995). Cytokine production by phytohemagglutinin-stimulated human blood cells: effects of corticosteroids, T cell immunosuppressants and phosphodiesterase IV inhibitors. Inflamm Res 44: 400-405.
56. Yiangou Y, Facer P, Durrenberger P, Chessell IP, Naylor A, Bountra C, etal. (2006). COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol 6: 12.